A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
Public ClinicalTrials.gov record NCT03412773. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 Versus Sorafenib as First-Line Treatment in Patients With Unresectable Hepatocellular Carcinoma
Study identification
- NCT ID
- NCT03412773
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- BeiGene
- Industry
- Enrollment
- 684 participants
Conditions and interventions
Conditions
Interventions
- Tislelizumab Drug
- Sorafenib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 17, 2017
- Primary completion
- Jul 10, 2022
- Completion
- Dec 13, 2023
- Last update posted
- Oct 13, 2025
2017 – 2023
United States locations
- U.S. sites
- 9
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Providence Medical Foundation | Fullerton | California | 92835 | — |
| UCLA Hematologyoncology | Los Angeles | California | 90095 | — |
| Chao Family Comprehensive Cancer Center | Orange | California | 92868 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Umdnj Njms | Newark | New Jersey | 07840 | — |
| Rj Zuckerberg Cancer Center | Lake Success | New York | 11042 | — |
| Xcancerdayton Physician Network | Dayton | Ohio | 45409 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| Ut Health San Antonio Mays Cancer Center | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 113 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03412773, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 13, 2025 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03412773 live on ClinicalTrials.gov.